Clinical Trials Directory

Trials / Unknown

UnknownNCT02352064

Evaluation of the Diagnostic Value of PET (18F-FDG) in Chronic Graft Versus Host Disease (cGVH)

EVALUATION OF THE DIAGNOSTIC VALUE OF PET (18F-FDG) IN CHRONIC GRAFT VERSUS HOST DISEASE (cGVH)

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
26 (estimated)
Sponsor
University Hospital, Caen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Allogeneic stem cell transplantation was developed to cure many patients with hematological malignancies. It results in the development of graft versus host disease (GVHD) in 30-70% of cases. Chronic GVHD diagnosis currently uses biopsies of affected organs (skin, liver, gastrointestinal tract) and / or the observation of typical clinical signs sufficient for diagnosis. However, the anatomical sites for biopsy including the digestive tract are not clearly identified (high or low biopsy) and may present risks in their realization in particular in patients weakened by blood disease or immunosuppression. PET-CT with 18F-FDG has already been evaluated in chronic inflammatory diseases such as Crohns disease with good sensitivity and specificity. It interest in the graft against the host was studied in acute forms of digestive and allows lesion mapping and monitoring the effectiveness of treatment. Among patients with chronic GVHD scleroderma form, PET with 18F-FDG enabled to view musculoskeletal uptakes localized to the affected areas identified with MRI. The investigators propose a study evaluating the sensitivity and specificity of the examination by PET-CT with 18F-FDG in the diagnosis of chronic GVHD compared to conventional diagnostic tools.

Detailed description

Patients will have PET/CT at day 150+/-15d post-hematopoietic stem cell transplantation (HSCT)

Conditions

Interventions

TypeNameDescription
PROCEDUREPET (18-FDG)Every patient will have a PET

Timeline

Start date
2015-01-01
Primary completion
2018-01-01
Completion
2018-01-01
First posted
2015-02-02
Last updated
2017-02-01

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02352064. Inclusion in this directory is not an endorsement.